Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial

Phase 4

Completed

• Conditions: Postmenopausal Osteoporosis

• Registration Number: NCT00239629
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The aim of this study is to directly compare the bone forming effects of 20 microg/day of teriparatide with those of 2 g/day strontium ranelate as measured by the histomorphometric variables and biochemical bone formation markers after 6 months of therapy in postmenopausal women with osteoporosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09
• Study First Submitted: 2005-10-13
• Study First Submitted QC: 2005-10-13
• Study First Posted: 2005-10-17
• Study Completion: 2007-01
• Status Verified: 2007-06
• Last Update Submitted: 2007-06-11
• Last Update Posted: 2007-06-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 73

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The primary efficacy measure is the mineralization surface (MS%BS) evaluated in double tetracycline stained bone biopsies.

Secondary Outcome Measures

Name	Time	Method
Other routine histomorphometric parameters, measured at visits 2, 3, 4, and 5.

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.; 🇪🇸 Madrid, Spain